pharmadog
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search

calendar

4,882 catalysts · 4,876 phase readout · 2,332 8k filing · 286 earnings · 274 pdufa · 129 phase 2 completion · 61 phase 1 completion

★ save view↓export CSV
next 91 dayslessmore
MonWedFri
2026-07-27: 2 catalysts2026-07-28: 4 catalysts2026-07-29: 12 catalysts2026-07-30: 12 catalysts2026-07-31: 3 catalysts2026-08-01: 0 catalysts2026-08-02: 0 catalysts2026-08-03: 4 catalysts2026-08-04: 12 catalysts2026-08-05: 14 catalysts2026-08-06: 10 catalysts2026-08-07: 1 catalyst2026-08-08: 0 catalysts2026-08-09: 0 catalysts2026-08-10: 1 catalyst2026-08-11: 1 catalyst2026-08-12: 1 catalyst2026-08-13: 0 catalysts2026-08-14: 0 catalysts2026-08-15: 0 catalysts2026-08-16: 0 catalysts2026-08-17: 0 catalysts2026-08-18: 1 catalyst2026-08-19: 0 catalysts2026-08-20: 0 catalysts2026-08-21: 0 catalysts2026-08-22: 0 catalysts2026-08-23: 0 catalysts2026-08-24: 0 catalysts2026-08-25: 0 catalysts2026-08-26: 0 catalysts2026-08-27: 0 catalysts2026-08-28: 0 catalysts2026-08-29: 0 catalysts2026-08-30: 0 catalysts2026-08-31: 0 catalysts2026-09-01: 1 catalyst2026-09-02: 0 catalysts2026-09-03: 0 catalysts2026-09-04: 0 catalysts2026-09-05: 0 catalysts2026-09-06: 0 catalysts2026-09-07: 0 catalysts2026-09-08: 0 catalysts2026-09-09: 0 catalysts2026-09-10: 0 catalysts2026-09-11: 0 catalysts2026-09-12: 0 catalysts2026-09-13: 0 catalysts2026-09-14: 0 catalysts2026-09-15: 0 catalysts2026-09-16: 0 catalysts2026-09-17: 0 catalysts2026-09-18: 0 catalysts2026-09-19: 0 catalysts2026-09-20: 0 catalysts2026-09-21: 0 catalysts2026-09-22: 0 catalysts2026-09-23: 0 catalysts2026-09-24: 0 catalysts2026-09-25: 0 catalysts2026-09-26: 0 catalysts2026-09-27: 0 catalysts2026-09-28: 0 catalysts2026-09-29: 0 catalysts2026-09-30: 0 catalysts2026-10-01: 0 catalysts2026-10-02: 0 catalysts2026-10-03: 0 catalysts2026-10-04: 0 catalysts2026-10-05: 0 catalysts2026-10-06: 0 catalysts2026-10-07: 0 catalysts2026-10-08: 0 catalysts2026-10-09: 0 catalysts2026-10-10: 0 catalysts2026-10-11: 0 catalysts2026-10-12: 0 catalysts2026-10-13: 0 catalysts2026-10-14: 0 catalysts2026-10-15: 0 catalysts2026-10-16: 0 catalysts2026-10-17: 0 catalysts2026-10-18: 0 catalysts2026-10-19: 0 catalysts2026-10-20: 1 catalyst2026-10-21: 0 catalysts2026-10-22: 1 catalyst2026-10-23: 0 catalysts2026-10-24: 0 catalysts2026-10-25: 0 catalysts
view
agendamonth
show past →
sort
soonestlatesttypesponsoralpha
type: phase readout×type: patent expiry×clear all
type
  • phase readout4,876
  • 8k filing2,332
  • earnings286
  • pdufa274
  • phase 2 completion129
  • phase 1 completion61
phase 1 initiation
32
  • phase 1 2 completion28
  • phase 0 trial completion22
  • phase 2 initiation16
  • therapy area
    • Infectious Disease6

    Date TBD

    50
    ›ENROLLING_BY_INVITATIONphase readoutNCT07448233: Application of an AI-Based Health Management System in Long-Term Epilepsy Management in Rural Areas

    Sponsor: Xijing Hospital. Phase: NA. Conditions: Epilepsies, Remote Management of Epilepsy in Rural Areas

    full page →ctgov ↗
    ›COMPLETEDphase readoutNCT02410733: Evaluation of the Safety and Tolerability of i.v. Administration of a Cancer Vaccine in Patients With Advanced Melanoma

    Sponsor: BioNTech SE. Phase: PHASE1. Conditions: Melanoma

    full page →ctgov ↗
    ›RECRUITINGphase readoutNCT04128748: Liposomal Cytarabine and Daunorubicin (CPX-351) and Quizartinib for the Treatment of Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome

    Sponsor: M.D. Anderson Cancer Center. Phase: PHASE1. Conditions: Acute Myeloid Leukemia, Blasts More Than 10 Percent of Bone Marrow Nucleated Cells, High Risk Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia, Recurrent Myelodysplastic Syndrome, Refractory Acute Myeloid Leukemia, Refractory Myelodysplastic Syndrome

    full page →ctgov ↗
    ›RECRUITINGphase readoutNCT07144826: Effects of a Probiotic Intervention on the Gut and Vaginal Microbiome in Patients With Advanced or Recurrent Ovarian Cancer Undergoing Treatment With Platinum Chemotherapy

    Sponsor: Ohio State University Comprehensive Cancer Center. Phase: EARLY_PHASE1. Conditions: Advanced Ovarian Carcinoma, Recurrent Ovarian Carcinoma, Stage II Ovarian Cancer AJCC v8, Stage III Ovarian Cancer AJCC v8, Stage IV Ovarian Cancer AJCC v8

    full page →ctgov ↗
    ›NOT_YET_RECRUITINGphase readoutNCT06206226: The Oh Happy Day Class - Digital Connections (OHDC-DC): A Pilot Study

    Sponsor: University of Wisconsin, Madison. Phase: NA. Conditions: Depression, Depressive Disorder, Depressive Symptoms

    full page →ctgov ↗
    ›COMPLETEDphase readoutNCT05116085: Efficacy and Safety of Tislelizumab (BGB-A317) as Neo-Adjuvant Treatment in Participants With Colorectal Cancer

    Sponsor: BeiGene. Phase: PHASE2. Conditions: Colorectal Cancer

    full page →ctgov ↗
    ›NOT_YET_RECRUITINGphase readoutNCT07512115: The Impact of 'A Miss Is as Good as a Mile': Is Compensation Necessary for Minimal Ocular Deviation in Myopic Laser Surgery?

    Sponsor: Zhongshan Ophthalmic Center, Sun Yat-sen University. Phase: NA. Conditions: Myopia, Refractive Ametropia

    full page →ctgov ↗
    ›RECRUITINGphase readoutNCT07532915: A Multicenter, Prospective, Randomized Controlled Study on EUS-Guided Precise Disconnection of Varices Versus Endoscopic Gastric Variceal Glue Injection for the Prevention of Gastric Variceal Bleeding.

    Sponsor: Nanfang Hospital, Southern Medical University. Phase: NA. Conditions: Gastric Variceal

    full page →ctgov ↗
    ›COMPLETEDphase readoutNCT00893035: Evaluation of an Apoptotic Test for Predicting Late Toxicities After Radiotherapy in Breast and Prostate Cancer Patients

    Sponsor: Institut du Cancer de Montpellier - Val d'Aurelle. Phase: . Conditions: Breast Cancer, Prostate Cancer

    full page →ctgov ↗
    ›COMPLETEDphase readoutNCT07324408: Multiple Ascending Dose Study of NH102 in Healthy Subjects

    Sponsor: Jiangsu Nhwa Pharmaceutical Co., Ltd.. Phase: PHASE1. Conditions: Depression

    full page →ctgov ↗
    ›RECRUITINGphase readoutNCT06760208: A Study to Learn More About Prevenar 20 Once it is Out in the Korean Market

    Sponsor: Pfizer. Phase: . Conditions: Pneumococcal Immunization, Safety

    full page →ctgov ↗
    ›NOT_YET_RECRUITINGphase readoutNCT07337408: Characterization of Weaning Practices in ICUs of Global South Countries

    Sponsor: Hospital do Coracao. Phase: . Conditions: Weaning From Mechanical Ventilation, Weaning Failure, Weaning From Mechanical Ventilation, Extubation

    full page →ctgov ↗
    ›RECRUITINGphase readoutNCT07542925: Prediction of Postoperative ICU Requirement in Oncologic Surgery

    Sponsor: Dr Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital. Phase: . Conditions: Neoplasms, Postoperative Complications, Perioperative/Postoperative Complications, Intensive Care Units

    full page →ctgov ↗
    ›RECRUITINGphase readoutNCT07232576: A Phase 2 Study to Evaluate the Efficacy, Safety and Pharmacokinetics of SHR-1139 in Patients With Moderate-to-severe Active Ulcerative Colitis

    Sponsor: Guangdong Hengrui Pharmaceutical Co., Ltd. Phase: PHASE2. Conditions: Adult Patients With Moderately to Severely Active Ulcerative Colitis

    full page →ctgov ↗
    ›RECRUITINGphase readoutNCT06357676: Glofitamab Plus Ibrutinib With Obinutuzumab for the Treatment of Patients With Mantle Cell Lymphoma, IGNITE MCL Trial

    Sponsor: OHSU Knight Cancer Institute. Phase: PHASE1. Conditions: Mantle Cell Lymphoma

    full page →ctgov ↗
    ›NOT_YET_RECRUITINGphase readoutNCT07038317: A Text Messaging Trial to Test Vaping Health Messages Optimized to Young Adults' Vaping Status

    Sponsor: University of Hawaii. Phase: NA. Conditions: Vaping Behaviors, Message Exposure, Young Adults

    full page →ctgov ↗
    ›COMPLETEDphase readoutNCT06614140: Personalized Neoantigen Cancer Vaccine for Patients With Solid Tumors

    Sponsor: Seqker Biosciences, Inc.. Phase: PHASE1. Conditions: Cancer, Solid Tumor, Adult

    full page →ctgov ↗
    ›COMPLETEDphase readoutNCT07323589: Impact of Myo-Inositol Alone vs Myo-Inositol Plus Metformin on Conception, Adherence, and Tolerability in PCOS

    Sponsor: PAEC general hospital. Phase: PHASE3. Conditions: PCOS (Polycystic Ovary Syndrome)

    full page →ctgov ↗
    ›RECRUITINGphase readoutNCT07202650: THE EFFECT OF GUİDED IMAGERY ON PREMENSTRUAL SYNDROME

    Sponsor: Baskent University. Phase: NA. Conditions: Guided Imagery, Premenstrual Syndrome, Nursing

    full page →ctgov ↗
    ›COMPLETEDphase readoutNCT01765374: Study of Sonographic Efficacy of Rituximab in Rheumatoid Arthritis

    Sponsor: University Hospital, Rouen. Phase: PHASE4. Conditions: Rheumatoid Arthritis

    full page →ctgov ↗
    ›RECRUITINGphase readoutNCT05436418: The Lowest Effective Dose of Post-Transplantation Cyclophosphamide in Combination With Sirolimus and Mycophenolate Mofetil as Graft-Versus-Host Disease Prophylaxis After Reduced Intensity Conditioning and Peripheral Blood Stem Cell Transplantation

    Sponsor: National Cancer Institute (NCI). Phase: PHASE1. Conditions: Peripheral Blood Stem Cell Transplantation, Hematopoietic Stem Cell Transplantation

    full page →ctgov ↗
    ›ACTIVE_NOT_RECRUITINGphase readoutNCT04626518: Substudy 03B: A Study of Immune and Targeted Combination Therapies in Participants With Second Line Plus (2L+) Renal Cell Carcinoma (MK-3475-03B/KEYMAKER-U03)

    Sponsor: Merck Sharp & Dohme LLC. Phase: PHASE1. Conditions: Carcinoma, Renal Cell

    full page →ctgov ↗
    ›NOT_YET_RECRUITINGphase readoutNCT07074418: Effect of Empagliflozin in Patients With eGFR Between 10 and 20 ml/Min/1.73m2

    Sponsor: Centre Hospitalier Universitaire de Nice. Phase: PHASE4. Conditions: Chronic Kidney Diseases

    full page →ctgov ↗
    ›RECRUITINGphase readoutNCT06121297: RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus

    Sponsor: Cabaletta Bio. Phase: PHASE1. Conditions: Systemic Lupus Erythematosus, Lupus Nephritis

    full page →ctgov ↗
    ›COMPLETEDphase readoutNCT07314710: Factors Affecting Postural Awareness in Academics

    Sponsor: Kutahya Health Sciences University. Phase: . Conditions: Health Adult Subjects

    full page →ctgov ↗
    ›COMPLETEDphase readoutNCT07478913: Predictive Value of Endobronchial Sonographic Patterns in Diagnosis of Mediastinal Lymphadenopathy

    Sponsor: Ain Shams University. Phase: . Conditions: Endobronchial Sonographic Patterns

    full page →ctgov ↗
    ›NOT_YET_RECRUITINGphase readoutNCT07427420: Postoperative Pain After Pulpectomy in Primary Molars

    Sponsor: Cairo University. Phase: NA. Conditions: Irreversible Pulpitis

    full page →ctgov ↗
    ›TERMINATEDphase readoutNCT06487858: A Study of BGB-R046 as Monotherapy and in Combination With Tislelizumab in Solid Tumors

    Sponsor: BeOne Medicines. Phase: PHASE1. Conditions: Solid Tumor

    full page →ctgov ↗
    ›RECRUITINGphase readoutNCT07343258: Pilot Study on Follow-Up of (Acutely) Suicidal Individuals From the Flemish Suicide Helpline

    Sponsor: University Ghent. Phase: NA. Conditions: Suicide, Suicidal Ideation and Behavior, Crisis Intervention

    full page →ctgov ↗
    ›ACTIVE_NOT_RECRUITINGphase readoutNCT06652958: A Study to Assess the Safety and Pharmacokinetics of a Human Monoclonal Antibody (VH4527079) in Healthy Adults and Persons With HIV

    Sponsor: ViiV Healthcare. Phase: PHASE1. Conditions: HIV Infections

    full page →ctgov ↗
    ›RECRUITINGphase readoutNCT04450758: Acute Colon Resection Versus Bridge to Colon Surgery With Stent or Stoma

    Sponsor: Skane University Hospital. Phase: . Conditions: Colon Cancer

    full page →ctgov ↗
    ›COMPLETEDphase readoutNCT03726658: Zelquistinel in the Treatment of Adults With Major Depressive Disorder

    Sponsor: Syndeio Biosciences, Inc. Phase: PHASE1. Conditions: Major Depressive Disorder

    full page →ctgov ↗
    ›RECRUITINGphase readoutNCT05272826: Study of Iberdomide, Bortezomib, Dexamethasone With Isatuximab Added on Demand for ND-NTE MM Patients

    Sponsor: Canadian Myeloma Research Group. Phase: PHASE2. Conditions: Multiple Myeloma

    full page →ctgov ↗
    ›COMPLETEDphase readoutNCT05934526: Efficacy and Safety of Seralutinib in Adult Subjects With PAH (PROSERA)

    Sponsor: GB002, Inc.. Phase: PHASE3. Conditions: Pulmonary Arterial Hypertension

    full page →ctgov ↗
    ›RECRUITINGphase readoutNCT07101926: Monitoring of Anti-TFPI in Hemophilia

    Sponsor: Hospices Civils de Lyon. Phase: . Conditions: Hemophilia, Rebalancing Agents, Prophylaxis

    full page →ctgov ↗
    ›COMPLETEDphase readoutNCT03283878: Antibiotic Prophylaxis in Patients Undergoing Elective Total Knee Arthroplasty- Multi-center Trial

    Sponsor: Duke University. Phase: PHASE4. Conditions: Arthropathy of Knee, Antibiotic Prophylaxis

    full page →ctgov ↗
    ›RECRUITINGphase readoutNCT04227678: Postprandial Fatty Acid Metabolism in Subjects With Lipoprotein Lipase Deficiency

    Sponsor: Université de Sherbrooke. Phase: NA. Conditions: Lipoprotein Lipase Deficiency

    full page →ctgov ↗
    ›TERMINATEDphase readoutNCT00426985: Efficacy and Safety of Ketoprofen Topical Patch 20% in the Treatment of Pain Associated With Shoulder, Elbow or Knee Tendonitis or Bursitis

    Sponsor: APR Applied Pharma Research s.a.. Phase: PHASE3. Conditions: Tendonitis, Bursitis

    full page →ctgov ↗
    ›COMPLETEDphase readoutNCT03832985: Pediatric Reporting of Adult-Onset Genomic Results

    Sponsor: Geisinger Clinic. Phase: EARLY_PHASE1. Conditions: Hereditary Breast and Ovarian Cancer Syndrome, Lynch Syndrome, Familial Hypercholesterolemia

    full page →ctgov ↗
    ›TERMINATEDphase readoutNCT04058743: Nickel Sensitivity

    Sponsor: Rush University Medical Center. Phase: NA. Conditions: Knee Arthropathy, Allergic Reaction

    full page →ctgov ↗
    ›ACTIVE_NOT_RECRUITINGphase readoutNCT06457555: Knowledge Levels and Experiences of Intensive Care Nurses on the Prevention of Pressure Sores: Mixed Method

    Sponsor: Burdur Mehmet Akif Ersoy University. Phase: . Conditions: Nurses, Pressure Ulcer, Critical Care

    full page →ctgov ↗
    ›NOT_YET_RECRUITINGphase readoutNCT07451925: Prediction of Postoperative Pain Using Venous Cannulation Pain and Preoperative Anxiety Scores

    Sponsor: Fatih Sultan Mehmet Training and Research Hospital. Phase: . Conditions: Preoperative Anxiety, Postoperative Pain

    full page →ctgov ↗
    ›COMPLETEDphase readoutNCT03965325: FOcUs on Colorectal CAncer oUtcomes: Long-Term Study

    Sponsor: IHU Strasbourg. Phase: . Conditions: Colorectal Cancer

    full page →ctgov ↗
    ›RECRUITINGphase readoutNCT05066217: An Efficacy and Safety Study of Clemizole HCl in Patients With Lennox-Gastaut Syndrome

    Sponsor: Epygenix. Phase: PHASE3. Conditions: Lennox Gastaut Syndrome

    full page →ctgov ↗
    ›RECRUITINGphase readoutNCT06157840: Development of an mHealth Behavioral Sleep Medicine Intervention for Use During Medication Assisted Treatment for MOUD

    Sponsor: Medical University of South Carolina. Phase: NA. Conditions: Opioid Use Disorder, Poor Quality Sleep

    full page →ctgov ↗
    ›RECRUITINGphase readoutNCT07487740: A Food Effect Study to Evaluate the Relative Bioavailability of Nalbuphine Extended-Release Tablets (NAL ER) in Healthy Participants

    Sponsor: Trevi Therapeutics. Phase: PHASE1. Conditions: Healthy Participants

    full page →ctgov ↗
    ›ACTIVE_NOT_RECRUITINGphase readoutNCT04821089: A Study to Assess the Safety and Efficacy of IPN10200 in Adult Participants With Moderate to Severe Upper Facial Lines

    Sponsor: Ipsen. Phase: PHASE1. Conditions: Moderate to Severe Upper Facial Lines

    full page →ctgov ↗
    ›COMPLETEDphase readoutNCT02362750: Evaluating Cancer Survivorship Care Models

    Sponsor: George Washington University. Phase: . Conditions: Quality of Life, Cancer

    full page →ctgov ↗
    ›RECRUITINGphase readoutNCT06276491: Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors

    Sponsor: Xencor, Inc.. Phase: PHASE1. Conditions: Ovarian Cancer, Endometrial Cancer, Germ Cell Tumor, Testicular Germ Cell Tumor, Ovarian Germ Cell Tumor

    full page →ctgov ↗
    ›COMPLETEDphase readoutNCT07236918: The Concert Therapy Pilot Study for Stress Reduction and Wellbeing

    Sponsor: BeHnam KhodaRahmi. Phase: NA. Conditions: Stress Reduction, Psychological Wellbeing, Mental Health, Music Therapy

    full page →ctgov ↗
    ← prev
    page 18 of 98
    next →